Encainide is a new agent for treating ventricular arrhythmias. We attempted long-term oral therapy with encainide in 38 patients with recurrent, strikingly drug-refractory ventricular tachycardia. The usual daily dose of encainide was 150-250 mg divided into four or six doses. The mean period until withdrawal of encainide or the date of follow-up was 4.2 months. Encainide completely eliminated recurrence of ventricular tachycardia in 54% of the patients for 6 months of therapy and in 29% of the patients for 18-30 months of therapy. Twelve patients (32%) had side effects possibly due to encainide; in four, the arrhythmia may have been worsened by encainide. During chronic therapy, encainide increased the PR interval by 18% and the QRS duration by 32%. There was no significant change in the corrected QT interval. The presence of QRS prolongation appeared to correlate with antiarrhythmic effect. We conclude that encainide is a safe, welltolerated antiarrhythmic agent that is often effective against previously drug-refractory ventricular tachycardia.
ENCAINIDE is a benzanilide derivative recently introduced for treatment of ventricular arrhythmias in man. On the basis of microelectrodel and intracardiac electrophysiologic2' studies, it might best be classified as a type I antiarrhythmic agent. 4 In canine His-Purkinje tissue,' at a concentration of 10-5 M, encainide markedly depressed the rate of rise during phase 0 of the action potential, an action similar to that of other type I agents. Unlike quinidine and procainamide, however, encainide did not change the effective refractory period, and actually shortened action potential duration. In intact, anesthetized dogs in our laboratory,2 encainide prolonged the HV interval by 23% and QRS duration by 14% at a plasma concentration of 1 ,ug/ml, but did not significantly affect the AH interval or the corrected QT interval. Postpacing sinus node automaticity and atrial, atrioventricular nodal and ventricular refractory periods were also unaffected. In intracardiac electrophysiologic studies in man, we found that encainide increased the HV interval by 31% and QRS duration by 18% at a mean plasma concentration of 0.5 .tg/ml. 3 To assess the antiarrhythmic efficacy of encainide in man, we initiated chronic therapy in patients with lifethreatening, previously drug-refractory ventricular tachycardia.
Materials and Methods
least 12 hours before initiation of therapy with encainide. Therapy was begun with two 25-mg doses, given either i.v. or orally 6 hours apart. If these doses were well tolerated, dosages were slowly increased to a maximum of 300 mg/day, depending upon the therapeutic response. Electrocardiographic rhythm strips were recorded and the QRS width was analyzed before and 15 minutes after each i.v. dose or 45 minutes after oral dose. Encainide dosage was reduced if the QRS width increased more than 40% in patients without previous intraventricular conduction delay or more than 25% in patients with QRS width greater than 0.12 second before encainide therapy. Frequency of dosing (every 4, 6, or 8 hours) was determined by examining continuous monitoring records for breakthrough of ventricular arrhythmias at the end of dosing intervals. A schedule with the least frequent dosing possible but without arrhythmia breakthrough was chosen for chronic therapy. After stable dosing was achieved, which required 3-6 days, 12-lead ECGs were obtained in the middle of a dosing interval for comparison with the ECG obtained before administration of encainide. Outpatients were initially seen weekly, and the frequency of visits was eventually decreased to once every 6 months after the first year. Follow-up included physical examination, standard blood chemistry screening* and 12-lead ECGs at each visit. All patients who received encainide for 1 month or longer underwent 24-hour continuous electrocardiographic monitoring at least once every 3 months.
Drug efficacy and inefficacy were defined as follows. A failure of therapy with a previous drug was counted when symptomatic ventricular tachcycardia had occurred when plasma concentrations of the drug were within the usual therapeutic range or when dosing was considered adequate on the basis of dose amounts and frequencies. Therapy was considered to have failed if the drug caused side effects necessitating discontinua-*Sodium, chloride, potassium, bicarbonate, urea nitrogen, creatinine, glucose, calcium, phosphorus, uric acid, cholesterol, total protein, albumin, bilirubin, alkaline phosphatase, LDH, SGOT, and complete blood count. tion of therapy. Encainide was considered effective if all symptoms of ventricular tachycardia, and therefore the need for hospitalization, were eliminated, unless symptomatic ventricular tachycardia was detected by electrocardiographic monitoring. For assessment of initial efficacy of encainide, all patients were monitored continuously in a cardiac surveillance unit where arrhythmia frequency was analyzed by computer and recorded on hard copy by a Hewlett Packard monitoring system. In addition, 25 of the patients underwent 24-hour continuous electrocardiographic monitoring using a Holter tape recording system before and after initiation of encainide therapy. Efficacy assessment by ambulatory monitoring might be considered superfluous in this group of patients due to the extraordinarily severe and symptomatic nature of their arrhythmias. Nevertheless, encainide was not considered effective if asymptomatic episodes of ventricular tachycardia lasting more than five beats were documented during in-hospital or ambulatory monitoring.
Encainide concentration was determined by a radioimmunoassay technique that measures only the parent compound. Twenty-four-hour electrocardiographic tape recordings were digitized and ventricular ectopic activity was quantified by a computer program developed at Stanford.5
Results
Patient Characteristics (table 1) Thirty-eight patients were treated with encainide for the purpose of suppressing ventricular tachycardia. The group included 30 men and eight women with a mean age of 56.5 ± 15.0 years (SD) (range 22-78 years). Twenty-six patients had underlying coronary artery disease. Six had myocardial disease resulting either from long-standing valvular heart disease or from idiopathic cardiomyopathy. No heart disease, aside from the ventricular arrhythmia, could be identified in six patients. Twenty-eight patients had significant congestive heart failure requiring medical treatment and restriction of activities.
Arrhythmia Severity (table 2) All patients had had at least three documented symptomatic episodes of ventricular tachycardia in the 6 months preceding therapy with encainide, and 
Encainide Dosage
In each patient, an attempt was made to attain effective therapy with the lowest possible dose and least frequent administration. Encainide was effective in a dose below 100 mg/day in only one subject and was prescribed in doses greater than 250 mg/day in only two patients (table 3) . Most patients were treated with 150-250 mg/day. Dose frequency varied from three to six times a day. Most patients were adequately managed with three or four daily doses.
Efficacy of Encainide
The 38 patients have been treated with encainide for a total of 160 months, with a maximal duration of therapy of 30 months. The mean follow-up period for all patients while on therapy was 4.2 months. Eleven patients (29%) failed to respond to encainide due to recurrence of their arrhythmias within 1 month of initiation of therapy (two of whom had had only asymptomatic brief runs of ventricular tachycardia on ambulatory monitoring). Six others were withdrawn from encainide during the first month, without arrhythmia recurrence or adverse side effects, to undergo alternate therapy. The mean follow-up period for the 21 patients treated for more than 1 month is 7.8 + 6.4 months. Seven of these 21 patients had late drug failures at 2, 2, 5, 5, 7, 14 and 15 months of therapy. In four of them, failure was a result of sudden death, and in the other three, a result of documented recurrence of ventricular tachycardia.
Life-table analysis" of the antiarrhythmic efficacy of encainide is illustrated in figure 1. Fifty-four percent of patients not withdrawn from therapy continued without documented recurrences of ventricular tachycardia or associated symptoms for 6 months of therapy, and 29% remained adequately treated with encainide for up to 30 months.
Electrocardiographic Effects
In table 4, control values for the PR interval, the QRS duration, and the corrected QT interval are compared with those determined from 12-lead ECGs obtained after achievement of stable chronic dosing with encainide. Both the PR and QRS intervals increased significantly, by 0.03 second. The 32% increase in QRS duration was readily apparent on 12-lead ECGs (fig. 2 ). In one patient with previously normal QRS duration, typical left bundle branch block developed during treatment with encainide. Although this change was not associated with symptoms or atrioventricular block, the encainide dose was reduced and the' left bundle branch block pattern resolved. In another patient, a rate-related right bundle branch block pattern developed, but the encainide dose was not altered. Another patient with a pre-encainide QRS duration of 0.12 second and an HV interval of 65 msec experienced complete right bundle branch block during treatment with encainide. Permanent dose reduction was not possible, as it was associated with recurrence of ventricular tachycardia. The QRS duration was 0.12 second or greater in four patients before treatment with encainide. However, no patient developed documented secondor third-degree atrioventricular block during treatment with encainide.
Side Effects of Encainide
Twenty-six of the 38 patients (68%) reported no side effects (table 5). The other 12 patients had 24 adverse effects, possibly due to encainide. Eight patients experienced neurologic side effects, including one or more of the following symptoms: a sensation of diz- ziness, mild ataxia, tremor and difficulty with visual accommodation. Two subjects reported transient gastrointestinal symptoms, including nausea and constipation. Four subjects have had persistent headache during encainide therapy. It was not necessary to discontinue encainide in any patient because of the above side effects. Dose reduction appeared to improve neurologic side effects in two patients, but their doses were eventually increased again without worsening of symptoms. No blood chemistry abnormalities developed during therapy with encainide.
Encainide appeared to worsen the ventricular arrhythmia in four patients. One of these patients had No 3, MARCH 1981 an increase in the frequency of paroxysmal ventricular tachycardia, which had been occurring daily, to multiple daily episodes. Each of the other three had episodes of ventricular tachycardia that deteriorated to ventricular fibrillation, requiring DC cardioversion and cardiopulmonary resuscitation. Each of these patients had also suffered ventricular tachycardia and fibrillation requiring cardiopulmonary resuscitation before treatment with encainide, but had not required resuscitative efforts for 48 hours before administration of encainide.
Plasma Concentration of Encainide
The daily dose required to control ventricular arrhythmias varied widely, ranging from 70-275 mg. There was an even more striking variability in effective plasma concentrations. Plasma concentrations throughout the dosing interval were obtained in 19 of the study patients during effective chronic oral therapy. Because these patients were maintained on the lowest effective dose, their plasma concentration determinations represent a reasonable estimate of the range of therapeutic concentrations. This range was 0.6-432 ng/ml. Four patients experienced effective therapy with plasma concentrations of encainide less than 10 ng/ml, suggesting the possibility of an active, unmeasured metabolite. The wide variations in required dosage and achieved concentration in these patients is in part a result of large intersubject differences in bioavailability and drug clearance (Winkle RA: unpublished observations), and may also depend upon differences in conversion of encainide to active metabolites. Based on our experience with these patients, it seems impossible to suggest a desired therapeutic concentration range, as effective concentrations spanned nearly three orders of magnitude.
Discussion
These data show that encainide may be an effective antiarrhythmic agent in patients with severe, previously drug-refractory ventricular tachycardia (table 2). Most of the patients had had more than 10 episodes of ventricular tachycardia in the month before encainide therapy, and more than half of the patients had required cardiopulmonary resuscitation and repeated and protracted hospitalization for attempted control of ventricular tachycardia. By lifetable analysis, 54% of patients treated with encainide have been effectively managed for 6 months, and six patients have been treated successfully for more than 1 year. Because all 38 patients had been unresponsive to (or unable to take) available, and in many cases, investigational antiarrhythmic agents, their rate of response to encainide is favorable.
Encainide is a unique antiarrhythmic agent. Its depressant effect upon dV/dt during phase zero of the action potential would qualify it as a type I agent in the system of Vaughan Williams.4 However, other type I agents also prolong action potential duration and effective refractory period, whereas encainide leaves the effective refractory period unchanged and actually shortens action potential duration. No other drug in common clinical use as an antiarrhythmic agent exerts this combination of effects upon the cardiac action potential. Encainide can be further distinguished from the classic type I agents (quinidine, procainamide and disopyramide) by its lack of vagolytic effects. These unique properties of encainide may account for its efficacy in patients with ventricular arrhythmias unresponsive to other antiarrhythmic agents.
Three actions of encainide are potentially antiarrhythmic. The first is its potent negative effect upon phase 0 of the action potential, which causes slowing of the His-Purkinje system and myocardial conduction in the intact heart. This could abolish ventricular tachycardia by producing complete conduction block within a reentry circuit. The second potentially antiarrhythmic effect of encainide, suppression of automaticity, has been shown in canine cardiac Purkinje fibers.1 Third, encainide decreases the action potential duration without changing the effective refractory period. This has been considered an antiarrhythmic action by some investigators, as it might be expected to result in more normal and uniformly propagated action potentials elicited early after the end of the effective refractory period.
Encainide caused relatively minor noncardiac side effects, none of which required withdrawal of therapy. This might also be considered unique among antiarrhythmic agents, because side effects often limit therapy with currently available drugs. 7 We have found that encainide has no measurable hemodynamic effects in patients without congestive heart failure, and mild negative hemodynamic effects in patients with symptomatic congestive heart failure (unpublished observations). This low incidence of adverse effects may make encainide desirable for use in patients with ventricular arrhythmias less severe and refractory than those of the patients in this report.
Encainide may have worsened the ventricular tachyarrhythmia in four patients. Because of the severity and frequency of their arrhythmias, it is impossible to implicate encainide as a cause of ventricular arrhythmias in this group of patients. Although even an 1 1% incidence (four of 38) of ventricular tachyarrhythmia enhancement is in keeping with experiences with other antiarrhythmic agents,8 careful attention must be paid to the possibility of arrhythmia enhancement by encainide. Encainide therapy should not be initiated in outpatients.
Encainide's electrocardiographic effects might be considered an important disadvantage. QRS prolongation of the degree routinely seen with encainide therapy has often been associated with actual or impending cardiac toxicity during therapy with quinidine and procainamide. However, other investigators have found a relationship between lengthening of the duration of the QRS complex and antiarrhythmic effect of encainide.9 The extent of QRS prolongation may be the most accurate variable by which to judge adequacy or excessiveness of dosing.
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Because of the striking intersubject variability of plasma concentrations and the exceedingly broad range of therapeutic concentrations of encainide, determinations of the plasma level of the parent compound will probably not afford clinically useful information for dosage adjustments. Considerable prolongation of the QRS duration, and of the PR interval as well, has occurred without drug-induced progression to infranodal conduction block in our patients. Encainide appears to be worthy of efficacy trials in larger groups of patients with ventricular arrhythmias. We would recommend that in the majority of patients it be given every 6 hours in a total daily dose of 100-250 mg. Therapy with encainide should be initiated in the hospital under continuous cardiac monitoring, and careful attention should be paid to its effects on QRS duration. Pharmacokinetic studies, including a search for active metabolites, assessment of long-term safety and more extensive use of encainide in patients with less severe, refractory ventricular arrhythmias, are required before definitive recommendations can be offered regarding its use.
